CoChat

Posttranslational regulation of Akt in human cancer

Open access
Chan, Chia-Hsin, Jo, Ukhyun, Kohrman, Abraham, Rezaeian, Abdol Hossein, Chou, Ping-Chieh, Logothetis, Christopher, Lin, Hui-Kuan · 2014 · Cell & Bioscience
Cited by 140

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Akt regulates critical cellular processes including cell survival and proliferation, glucose metabolism, cell migration, cancer progression and metastasis through phosphorylation of a variety of downstream targets. The Akt pathway is one of the most prevalently hyperactivated signaling pathways in human cancer, thus, research deciphering molecular mechanisms which underlie the aberrant Akt activation has received enormous attention. The PI3K-dependent Akt serine/threonine phosphorylation by PDK1 and mTORC2 has long been thought to be the primary mechanism accounting for Akt activation. However, this regulation alone does not sufficiently explain how Akt hyperactivation can occur in tumors with normal levels of PI3K/PTEN activity. Mounting evidence demonstrates that aberrant Akt activation can be attributed to other posttranslational modifications, which include tyrosine phosphorylation, O-GlcNAcylation, as well as lysine modifications: ubiquitination, SUMOylation and acetylation. Among them, K63-linked ubiquitination has been shown to be a critical step for Akt signal activation by facilitating its membrane recruitment. Deficiency of E3 ligases responsible for growth factor-induced Akt activation leads to tumor suppression. Therefore, a comprehensive understanding of posttranslational modifications in Akt regulation will offer novel strategies for cancer therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/2045-3701-4-59

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 83

  1. Bellacosa A, Testa JR, Staal SP, Tsichlis PN: A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991, 254: 274-277. 10.1126/science.1833819 · DOI · Paper page
  2. Bellacosa A, Franke TF, Gonzalez-Portal ME, Datta K, Taguchi T, Gardner J, Cheng JQ, Testa JR, Tsichlis PN: Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications. Oncogene. 1993, 8: 745-754.
  3. Coffer PJ, Woodgett JR: Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991, 201: 475-481. 10.1111/j.1432-1033.1991.tb16305.x · DOI · Paper page
  4. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F, Hemmings BA: Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci U S A. 1991, 88: 4171-4175. 10.1073/pnas.88.10.4171 · DOI · Paper page
  5. Eijkelenboom A, Burgering BM: FOXOs: signalling integrators for homeostasis maintenance. Nat Rev Mol Cell Biol. 2013, 14: 83-97. 10.1038/nrm3507 · DOI · Paper page
  6. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997, 91: 231-241. 10.1016/S0092-8674(00)80405-5 · DOI · Paper page
  7. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999, 401: 82-85. 10.1038/43466 · DOI · Paper page
  8. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009, 11: 397-408. 10.1038/ncb1847 · DOI · Paper page
  9. Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, Tempst P, Pandolfi PP: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009, 11: 420-432. 10.1038/ncb1849 · DOI · Paper page
  10. Chan CH, Lee SW, Wang J, Lin HK: Regulation of Skp2 expression and activity and its role in cancer progression. The Scientific World JOURNAL. 2010, 10: 1001-1015. · DOI · Paper page
  11. Chan CH, Gao Y, Moten A, Lin HK: Novel ARF/p53-independent senescence pathways in cancer repression. J Mol Med. 2011, 89: 857-867. 10.1007/s00109-011-0766-y · DOI
  12. Ecker K, Hengst L: Skp2: caught in the Akt. Nat Cell Biol. 2009, 11: 377-379. 10.1038/ncb0409-377 · DOI
  13. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304: 554. 10.1126/science.1096502 · DOI · Paper page
  14. Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006, 6: 184-192. 10.1038/nrc1819 · DOI · Paper page
  15. Fruman DA, Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014, 13: 140-156. 10.1038/nrd4204 · DOI · Paper page
  16. Gonzalez E, McGraw TE: The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle. 2009, 8: 2502-2508. 10.4161/cc.8.16.9335 · DOI · Paper page
  17. Gonzalez E, McGraw TE: Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 2009, 106: 7004-7009. 10.1073/pnas.0901933106 · DOI · Paper page
  18. Brazil DP, Park J, Hemmings BA: PKB binding proteins. Getting in on the Akt. Cell. 2002, 111: 293-303. 10.1016/S0092-8674(02)01083-8 · DOI · Paper page
  19. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15: 6541-6551. · DOI · Paper page
  20. Bozulic L, Surucu B, Hynx D, Hemmings BA: PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell. 2008, 30: 203-213. 10.1016/j.molcel.2008.02.024 · DOI · Paper page
  21. Feng J, Park J, Cron P, Hess D, Hemmings BA: Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem. 2004, 279: 41189-41196. 10.1074/jbc.M406731200 · DOI · Paper page
  22. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci U S A. 2000, 97: 3207-3212. 10.1073/pnas.97.7.3207 · DOI · Paper page
  23. Fayard E, Tintignac LA, Baudry A, Hemmings BA: Protein kinase B/Akt at a glance. J Cell Sci. 2005, 118: 5675-5678. 10.1242/jcs.02724 · DOI · Paper page
  24. Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, Wan L, Singh A, Zhai B, Yuan M, Wang Z, Gygi SP, Lee TH, Lu KP, Toker A, Pandolfi PP, Asara JM, Kirschner MW, Sicinski P, Cantley L, Wei W: Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature. 2014, 508: 541-545. 10.1038/nature13079 · DOI · Paper page
  25. Gao Y, Moten A, Lin HK: Akt: a new activation mechanism. Cell Res. 2014, 24: 785-786. 10.1038/cr.2014.57 · DOI
  26. Salmena L, Carracedo A, Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 2008, 133: 403-414. 10.1016/j.cell.2008.04.013 · DOI · Paper page
  27. Arroyo JD, Hahn WC: Involvement of PP2A in viral and cellular transformation. Oncogene. 2005, 24: 7746-7755. 10.1038/sj.onc.1209038 · DOI · Paper page
  28. Millward TA, Zolnierowicz S, Hemmings BA: Regulation of protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 1999, 24: 186-191. 10.1016/S0968-0004(99)01375-4 · DOI · Paper page
  29. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP: Identification of a tumour suppressor network opposing nuclear Akt function. Nature. 2006, 441: 523-527. 10.1038/nature04809 · DOI · Paper page
  30. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG: A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008, 132: 125-136. 10.1016/j.cell.2007.11.041 · DOI · Paper page
  31. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG: An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005, 122: 261-273. 10.1016/j.cell.2005.05.012 · DOI · Paper page
  32. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, Chen H, Qiu Y: Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem. 2001, 276: 31858-31862. 10.1074/jbc.C100271200 · DOI · Paper page
  33. Zheng Y, Peng M, Wang Z, Asara JM, Tyner AL: Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor. Mol Cell Biol. 2010, 30: 4280-4292. 10.1128/MCB.00024-10 · doi:10.1128/mcb.00024-10
  34. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G: Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature. 2009, 457: 1146-1149. 10.1038/nature07617 · DOI · Paper page
  35. Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schonbrunn E, Sebti SM, Earp HS, Mahajan NP: Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS One. 2010, 5: e9646. 10.1371/journal.pone.0009646 · DOI · Paper page
  36. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE: A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007, 448: 439-444. 10.1038/nature05933 · DOI · Paper page
  37. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68: 6084-6091. 10.1158/0008-5472.CAN-07-6854 · DOI · Paper page
  38. Tibes R, Kornblau SM, Qiu Y, Mousses SM, Robbins C, Moses T, Carpten JD: PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation. Br J Haematol. 2008, 140: 344-347. 10.1111/j.1365-2141.2007.06920.x · DOI
  39. Chen ZJ, Sun LJ: Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell. 2009, 33: 275-286. 10.1016/j.molcel.2009.01.014 · DOI · Paper page
  40. Bhoj VG, Chen ZJ: Ubiquitylation in innate and adaptive immunity. Nature. 2009, 458: 430-437. 10.1038/nature07959 · DOI · Paper page
  41. Corn JE, Vucic D: Ubiquitin in inflammation: the right linkage makes all the difference. Nat Struct Mol Biol. 2014, 21: 297-300. 10.1038/nsmb.2808 · DOI
  42. Hoeller D, Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 2009, 458: 438-444. 10.1038/nature07960 · DOI · Paper page
  43. Segref A, Hoppe T: Think locally: control of ubiquitin-dependent protein degradation in neurons. EMBO Rep. 2009, 10: 44-50. 10.1038/embor.2008.229 · DOI · Paper page
  44. Adhikari A, Chen ZJ: Diversity of polyubiquitin chains. Dev Cell. 2009, 16: 485-486. 10.1016/j.devcel.2009.04.001 · DOI
  45. Yang WL, Wu CY, Wu J, Lin HK: Regulation of Akt signaling activation by ubiquitination. Cell Cycle. 2010, 9: 487-497.
  46. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N: Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res. 2003, 63: 2139-2144.
  47. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q: Negative regulation of AKT activation by BRCA1. Cancer Res. 2008, 68: 10040-10044. 10.1158/0008-5472.CAN-08-3009 · DOI
  48. Suizu F, Hiramuki Y, Okumura F, Matsuda M, Okumura AJ, Hirata N, Narita M, Kohno T, Yokota J, Bohgaki M, Obuse C, Hatakeyama S, Obata T, Noguchi M: The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt. Dev Cell. 2009, 17: 800-810. 10.1016/j.devcel.2009.09.007 · DOI
  49. Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, Kim K, Kim J, An IS, Kim J, Um HD, Park IC, Lee SJ, Nam SY, Jin YW, Lee JH, An S: Akt is negatively regulated by the MULAN E3 ligase. Cell Res. 2012, 22: 873-885. 10.1038/cr.2012.38 · DOI
  50. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, Lin HK: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009, 325: 1134-1138. 10.1126/science.1175065 · DOI · Paper page
  51. Fan CD, Lum MA, Xu C, Black JD, Wang X: Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem. 2013, 288: 1674-1684. 10.1074/jbc.M112.416339 · DOI · Paper page
  52. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK: The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell. 2012, 149: 1098-1111. 10.1016/j.cell.2012.02.065 · DOI · Paper page
  53. Li W, Peng C, Lee MH, Lim D, Zhu F, Fu Y, Yang G, Sheng Y, Xiao L, Dong X, Ma W, Bode AM, Cao Y, Dong Z: TRAF4 is a critical molecule for Akt activation in lung cancer. Cancer Res. 2013, 73: 6938-6950. 10.1158/0008-5472.CAN-13-0913 · DOI
  54. Lim JH, Jono H, Komatsu K, Woo CH, Lee J, Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, Park SH, Kim YI, Choi YD, Shen H, Heo KS, Xu H, Bourne P, Koga T, Xu H, Yan C, Wang B, Chen LF, Feng XH, Li JD: CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun. 2012, 3: 771. · DOI · Paper page
  55. Yang WL, Jin G, Li CF, Jeong YS, Moten A, Xu D, Feng Z, Chen W, Cai Z, Darnay B, Gu W, Lin HK: Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal. 2013, 6: ra3.
  56. Li R, Wei J, Jiang C, Liu D, Deng L, Zhang K, Wang P: Akt SUMOylation regulates cell proliferation and tumorigenesis. Cancer Res. 2013, 73: 5742-5753. 10.1158/0008-5472.CAN-13-0538 · DOI · Paper page
  57. Risso G, Pelisch F, Pozzi B, Mammi P, Blaustein M, Colman-Lerner A, Srebrow A: Modification of Akt by SUMO conjugation regulates alternative splicing and cell cycle. Cell Cycle. 2013, 12: 3165-3174. · DOI
  58. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP: The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011, 4: ra46. · DOI · Paper page
  59. Vosseller K, Wells L, Lane MD, Hart GW: Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 2002, 99: 5313-5318. 10.1073/pnas.072072399 · DOI · Paper page
  60. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, Kudlow JE, Michell RH, Olefsky JM, Field SJ, Evans RM: Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature. 2008, 451: 964-969. 10.1038/nature06668 · DOI · Paper page
  61. Soesanto YA, Luo B, Jones D, Taylor R, Gabrielsen JS, Parker G, McClain DA: Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol Endocrinol Metab. 2008, 295: E974-E980. 10.1152/ajpendo.90366.2008 · DOI
  62. Wang S, Huang X, Sun D, Xin X, Pan Q, Peng S, Liang Z, Luo C, Yang Y, Jiang H, Huang M, Chai W, Ding J, Geng M: Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One. 2012, 7: e37427. 10.1371/journal.pone.0037427 · DOI
  63. Shi J, Wu S, Dai CL, Li Y, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX: Diverse regulation of AKT and GSK-3beta by O-GlcNAcylation in various types of cells. FEBS Lett. 2012, 586: 2443-2450. 10.1016/j.febslet.2012.05.063 · DOI
  64. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4: 988-1004. 10.1038/nrd1902 · DOI · Paper page
  65. Liu P, Cheng H, Roberts TM, Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009, 8: 627-644. 10.1038/nrd2926 · DOI · Paper page
  66. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006, 9: 341-349. 10.1016/j.ccr.2006.03.029 · DOI · Paper page
  67. Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 2009, 15: 4147-4156. 10.1158/1078-0432.CCR-08-2814 · DOI · Paper page
  68. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G: Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009, 69: 143-150. 10.1158/0008-5472.CAN-07-6656 · DOI · Paper page
  69. Porta C, Paglino C, Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 2014, 4: 64. · DOI · Paper page
  70. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011, 19: 575-586. 10.1016/j.ccr.2011.04.008 · DOI · Paper page
  71. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG, Wu H: Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011, 19: 792-804. 10.1016/j.ccr.2011.05.006 · DOI · Paper page
  72. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J: PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011, 30: 2547-2557. 10.1038/onc.2010.626 · DOI · Paper page
  73. Lin A, Piao HL, Zhuang L, Sarbassov dos D, Ma L, Gan B: FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res. 2014, 74: 1682-1693. 10.1158/0008-5472.CAN-13-1729 · DOI · Paper page
  74. Fensterle J, Aicher B, Seipelt I, Teifel M, Engel J: Current view on the mechanism of action of perifosine in cancer. Anti Cancer Agents Med Chem. 2014, 14: 629-635. 10.2174/1871520614666140309225912. 10.2174/1871520614666140309225912 · doi:10.2174/1871520614666140309225912
  75. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G: In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res. 2004, 14: 513-527. · DOI
  76. Wang Z, Liu P, Inuzuka H, Wei W: Roles of F-box proteins in cancer. Nat Rev Cancer. 2014, 14: 233-247. 10.1038/nrc3700 · DOI · Paper page
  77. Chan CH, Morrow JK, Zhang S, Lin HK: Skp2: a dream target in the coming age of cancer therapy. Cell Cycle. 2014, 13: 679-680. 10.4161/cc.27853 · DOI
  78. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N: Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 2001, 15: 2203-2208. 10.1101/gad.913901 · DOI · Paper page
  79. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemmings BA: Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development. 2005, 132: 2943-2954. 10.1242/dev.01864 · DOI · Paper page
  80. Stambolic V, Woodgett JR: Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol. 2006, 16: 461-466. 10.1016/j.tcb.2006.07.001 · DOI · Paper page
  81. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, Brugge JS: Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol. 2005, 171: 1023-1034. 10.1083/jcb.200505087 · DOI · Paper page
  82. Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S, Toker A: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 2005, 20: 539-550. 10.1016/j.molcel.2005.10.033 · DOI · Paper page
  83. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN: Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res. 2007, 67: 167-177. 10.1158/0008-5472.CAN-06-3782 · DOI · Paper page

Cited by

See all 140

Metadata

Authors
Chan, C.-H., Jo, U., Kohrman, A., Rezaeian, A. H., Chou, P.-C., Logothetis, C., & Lin, H.-K.
Venue
Cell & Bioscience
Published
2014-10-01
Volume
4
Issue
1
Pages
59-59
ISSN
2045-3701 (ISSN-L)
OpenAlex
W2097733751
Cited by
140
References
15
FWCI
5.96
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Posttranslational regulation of Akt in human cancer. https://app.cochat.ai/papers/10.1186/2045-3701-4-59
The paper
Chan, C.-H., Jo, U., Kohrman, A., Rezaeian, A. H., Chou, P.-C., Logothetis, C., & Lin, H.-K. (2014). Posttranslational regulation of Akt in human cancer. Cell & Bioscience. https://doi.org/10.1186/2045-3701-4-59

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.